A rapid psa half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer

Journal of the Canadian Urological Association

Volumn 3, Issue 5, 2009, Pages 369-374

  Hanninen, Mikael ^b   Venner, Peter ^a   North, Scott ^a  

^a CROSS CANCER INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70350500423     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel and prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
2. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
3. Beer TM, Pierce WC, Lowe BA, et al. Phase II study of weekly docetaxel in symptomatic androgenindependent prostate cancer. Ann Oncol 2001:12:1273-9.
4. Berry W, Dakhil S, Gregurich MA, et al. Phase II trial of single-agent weekly docetaxel in hormonerefractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001;28:Suppl 15:8-15.
5. Friedland D, Cohen J, Miller R Jr, et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumour effect to phosphorylation of Bcl-2. Semin Oncol 1999;26:Suppl 17:19-23.
6. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999;26:Suppl 17:14-8.
7. Cho D, Di Blasio CJ, Rhee AC, et al.Prognostic factors for survival in patients with hormone-refractory prostate cancer after initial androgen deprivation therapy. Urol Oncol 2003;21:282-91.
8. Semeniuk RC, Venner PM, North S. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology 2006;68:565-9.
9. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-7.
10. Kelly WK, Scher HI, Mazumdar M, et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993;11:607-15.
11. Smith DC, Dunn RL, Strawderman MS, et al. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998;16:1835-43.
12. Sridhara R, Eisenberger MA, Sinibaldi VJ, et al. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 1995;13:2944-53.
13. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007;25:3965-70. (Pubitemid 47477275)